Emerald Logic
Our FACET software accelerates drug development with rapid biomarker discovery, quantitative diagnostics, and clinical trial enhancement.
- Stage Full Product Ready
- Industry Software
- Location Aliso Viejo, CA, USA
- Currency USD
- Founded March 2011
- Employees 2
- Website emeraldlogic.com
Company Summary
Emerald Logic is a pioneer in quantitative personalized medicine and biomarker discovery. The company’s FACET (FAst Collective Evolution Technology) software combines principles and math from biology, engineering, and particle physics to answer intractable questions with high human and economic impact.
Team
-
Patrick LilleyCEO
CEO 2 startups, 1 sold to HP for $160M, 1 to European firm for 10X in 1 year. VP Operations of start-up Microsoft bought for $275M. Grew a U.S. wireless subsidiary from zero to $5.5M in 1 year to support IPO. Public company division turnaround (1 yr): revenue up 3X, pipeline 27X, costs cut 33%.
Operations, marketing, business development, finance, product management, technology (9 patents).
Global hyper-growth expert, from start-up to $4.5 -
Patrick O'NeillCTO
CTO/founder of Digital Transit. Primary investor Nokia. Merged with Bitfone, sold to HP for $160M. CTO/founder of Deep Six Technologies. Sold to European firm in a year.
Contract problem solver: language converters, mobile, machine vision, multimedia, gaming, finance.
90+ patents filed (evolutionary computing, compression, large-scale systems, messaging security, etc.)
Consumer & enterprise software, mobile, multiplayer gaming, online
-
Milton LohrAdvisor
Former Undersecretary of Defense for Acquisition, NATO acquisitions representative, entrepreneur, independent defense & space professional.
-
Babak HassibiAdvisor
Professor & Executive Officer of Electrical Engineering, Cal Tech; former Bell Labs Tech Staff.
-
Ashwin RanganAdvisor
CIO of Edwards Lifesciences, CIO of Walmart.com, CIO of Conexant, Consulting CIO to Bank of America.
-
Kevin HorganAdvisor
Seasoned physician scientist with executive leadership experience in development of large and small molecules across multiple therapeutic areas. Pediatric and orphan drug development expertise. Extensive regulatory agency interactions and presentations including FDA Advisory Committees.
SpecialtiesClinical development of novel therapies and diagnostics, translational medicine, personalized medicine, risk management, bayesian thinking and "bi
Previous Investors
-
Various angel investors (current seed round)Unconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.